Aurobindo USA receives FTC clearance for Lannett acquisition

Aurobindo Pharma USA has received FTC clearance to acquire Lannett. The deal is expected to close before the end of June 2026.

AbbVie to acquire Apogee and expand immunology pipeline

AbbVie plans to acquire Apogee for about $10.9 billion, adding clinical immunology assets for atopic dermatitis and asthma.

Johnson & Johnson invests over $1 billion in Jacksonville vision operations

Johnson & Johnson will invest more than $1 billion in Jacksonville to expand ACUVUE contact lens manufacturing, packaging and distribution.

GSK to acquire Nuvalent in $10.6 billion oncology deal

GSK agreed to buy Nuvalent for $10.6 billion, adding late-stage lung cancer assets and broadening its oncology growth platform.

Germany backs away from variable drug discount plan

Germany will drop a variable discount plan for branded drugs, Reuters reports, after pharmaceutical companies warned of investment cuts.

Established medicines need renewed focus

Christopher Hähner of Good Healthcare Pharma says established medicines need active lifecycle management despite the industry's innovation focus.

Bayer CEO Bill Anderson warns of Germany’s competitiveness gap

Bayer CEO Bill Anderson says high energy costs and bureaucracy put Germany at a disadvantage. He also warns of fertilizer risks linked to Hormuz disruptions.

Boehringer Ingelheim halts planned investment in Germany

Boehringer Ingelheim is halting €900 million in planned investment in Germany for 2027 to 2030, citing policy-related and location factors.

Italy probes Biogen over Tysabri test and market abuse claims

Italy’s AGCM is investigating Biogen over alleged market abuse tied to anti-JCV testing for Tysabri, with potential effects on Sandoz.

Biogen completes acquisition of Apellis Pharmaceuticals

Biogen has completed its acquisition of Apellis. The deal adds SYFOVRE and EMPAVELI and is positioned to support Biogen’s nephrology expansion.

Health system under pressure: sustainability as a lever for prevention

At WeACT Con, experts discussed how prevention and environmental health can reduce risks and help stabilize healthcare, from funding ideas to guidance.

Bedrocan flower to be offered as Becanex PIEX raw extract for compounding

Bedrocan and Becanex plan PIEX Bedrocan 70% THC as a raw extract for pharmacy compounding, with shipments expected to start in summer 2026.

Vetter breaks ground on new production site in Saarlouis

Vetter has started construction of a new production site in Saarlouis. The first phase includes a 50,000 m² building, with start-up planned for 2031.

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Angelini Pharma has agreed to buy Catalyst for $4.1bn in cash, entering the U.S. market. The companies expect the deal to close in Q3 2026.

UEFA appoints Haleon as first medicine and health partner

UEFA has named Haleon its first partner for medicine and health. The multi-year collaboration focuses on evidence-based pain management in football.

Daiichi Sankyo honors patient initiatives with O-Mamori Award 2026

Daiichi Sankyo presented the O-Mamori Award 2026 in Berlin. Eight cardiology and oncology patient initiatives share 30,000 euros in prize money.

Gilead Extends Tender Offer for Arcellx

Gilead has extended its tender offer to acquire Arcellx until April 24, 2026. The offer remains $115 per share in cash plus a CVR.

IQVIA: German pharma market up in value in 2025, volumes slightly down

IQVIA reports 5.7% sales growth in Germany’s pharma market in 2025, while volumes slipped by 0.7%. In pharmacies, Rx grew faster than OTC.

Gilead to acquire Ouro Medicines for clinical BCMAxCD3 program

Gilead Sciences plans to buy Ouro Medicines for up to $2.175bn, adding OM336, a clinical BCMAxCD3 T cell engager for autoimmune diseases.

Hims & Hers shifts US weight loss strategy with Novo Nordisk deal

Hims & Hers is refocusing its US weight loss business and teaming up with Novo Nordisk, prioritizing access to a wider set of FDA-approved GLP-1 drugs.